By Clinical Informatics News Staff

June 21, 2017 | Deloitte has announced the debut of a global initiative to launch an innovative integrated solution for the pharmacovigilance capabilities of Daiichi Sankyo. Powered by Deloitte's high-performance ConvergeHEALTH Safety platform, Daiichi Sankyo expects to significantly heighten the precision, depth and agility of insight extraction, enable proactive insight driven decision- making, and increase operational effectiveness across all of Daiichi Sankyo's global entities. Deloitte is also tasked with upgrading Daiichi Sankyo's existing transactional case processing system to deliver valuable efficiencies.

ConvergeHEALTH Safety's innovative capabilities and modern architecture will facilitate consolidation of multiple global systems into one and enhance Daiichi Sankyo's capabilities with advanced predictive analytics, global and Japanese aggregate reporting, and compliance monitoring capabilities. A transactional system upgrade will further enhance compliance monitoring and quality for adverse event case processing.

"With the increasing complexity of global regulatory and compliance requirements and the growing volume of adverse events, life sciences organizations require advanced capabilities across the pharmacovigilance life-cycle," Greg Reh, principal, Deloitte Consulting and global life sciences and health care leader, wrote in a statement. "The new solution will work to proactively and cost effectively address their complex business issues and processes around safety risk and compliance. It draws from Deloitte's hands-on experience with the safety domain, deep life sciences industry knowledge, our own technology intellectual property, and continuous innovation with industry and academia."